New ICER and PHIL data show drug launch prices soaring while patients, especially on Medicare, struggle to access needed care ...

Dren Bio has closed an oversubscribed $350 million private financing round to advance its lead antibody candidate toward ...

Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.

Recent court rulings and USPTO guidance reshape how biotech startups should approach patent strategy for drugs and ...

Flagship has merged 3 of its own portfolio companies into a single powerhouse aimed at predicting how drugs will work before ...

A ten-member European consortium led by Exogenus Therapeutics has secured $14.4 million to develop a disease-modifying ...

“The acquisition of Gameto broadens our scientific capabilities with their novel cell-engineering platform, creating potential to address unmet needs in reproductive health,” a spokesperson for ...